INmune Bio, Inc.

Contributing Author

Recent Articles by INmune Bio, Inc.

May-15	INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform INMB -7.74% GlobeNewswire
May-14	INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease INMB +15.07% GlobeNewswire
May-13	INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point INMB +5.04% GlobeNewswire
May-07	INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update INMB -5.92% GlobeNewswire
May-05	INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases INMB GlobeNewswire
Apr-30	INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th INMB +7.52% GlobeNewswire
Apr-16	INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models INMB GlobeNewswire
Mar-30	INmune Bio Inc. Announces 2025 Results and Provides Business Update INMB GlobeNewswire
Mar-24	INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. INMB GlobeNewswire
Mar-19	INmune Bio's MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer's Disease INMB GlobeNewswire
Feb-23	INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar INMB GlobeNewswire
Feb-19	INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom for RDEB INMB GlobeNewswire
Feb-12	INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's Disease INMB -6.37% GlobeNewswire
Feb-10	INmune Bio Advances CORDStrom Towards UK Marketing Authorization in RDEB INMB GlobeNewswire
Jan-27	INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives INMB +7.78% GlobeNewswire
Dec-05	Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom Platform INMB GlobeNewswire
Dec-01	INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients INMB -10.06% GlobeNewswire
Nov-18	INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference INMB GlobeNewswire
Oct-30	INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update INMB +5.78% INMB GlobeNewswire
Oct-23	INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 INMB GlobeNewswire
Oct-14	INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 INMB GlobeNewswire
Sep-29	INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal INMB GlobeNewswire
Sep-15	INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom at CGT Catapult INMB GlobeNewswire
Aug-07	INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes INMB -8.24% INMB GlobeNewswire
Aug-04	INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment INMB +11.52% GlobeNewswire
Jul-31	INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th INMB GlobeNewswire
Jul-29	INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro Presented at the Alzheimer's Association International Conference INMB +8.59% GlobeNewswire
Jul-24	INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimer's Association International Conference INMB GlobeNewswire
Jun-30	INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules INMB -56.66% INMB -9.52% GlobeNewswire
Jun-30	INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro in Early Alzheimer's Disease INMB -56.66% GlobeNewswire
Jun-27	INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules INMB -15.13% GlobeNewswire
Jun-26	INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th INMB -14.79% GlobeNewswire
Jun-10	XPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense INMB GlobeNewswire
May-14	INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference INMB -7.82% GlobeNewswire
May-08	INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update INMB GlobeNewswire
May-05	INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th INMB GlobeNewswire

INmune Bio, Inc.

Recent Articles by INmune Bio, Inc.

Upgrade your Finviz experience